MorbidityPhase 3NCT07297264
Betamethasone and Complications of Lower Third Molar Surgery
A Phase 3 study testing Betamethasone and normal saline in people with Morbidity and Third Molars Extraction, run by Shehab Ahmed Hamad at 1 site in Iraq.
Trial summary
Pain, swelling, and trismus are common sequalae of surgical removal of impacted third molars. The aim of this study is to evaluate effect of local administration of betamethasone, into the pterygomandibular space, on these sequalae Read more about this study
- Who is it for?
- Ages 18 to 35 years
- Conditions the study is for
- Morbidity, Third Molars Extraction, Steroid Injection
- What is being tested?
- Betamethasone and normal saline
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteIraq
- Study dates
- 3 Jan 2022to 26 Mar 2023
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- healthy
- no infection
- no pain
- no limitation of mouth opening
- symmetrical bilateral impacted third molars (Mesioangular, CLASS II, Position B
Who cannot join
- Infection
- systemic disease
- smokers
- operation time exceeding 30 minutes
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect of Betamethasone Injection Into the Pterygomandibular Space on Postoperative Sequelae of Impacted Lower Third Molar Surgery: A Randomized, Double-blind, Placebo-controlled Clinical Trial With a Split-mouth Design
Pain, swelling, and trismus are common sequalae of surgical removal of impacted third molars. The aim of this study is to evaluate effect of local administration of betamethasone, into the pterygomandibular space, on these sequalae
Read the detailed description
A prospective, single center, double-blind, randomized controlled design study was conducted between January 2022 and February 2023, in the department of oral and maxillofacial surgery, Rizgary teaching hospital, Erbil, Iraq. The participants were patients presented for the surgical removal of bilateral symmetrical impacted lower third molars. To achieve 95% power, a sample size of 40 patients with bilateral impacted third molars was required.
The study was approved by the Ethical Committee of the institutional board and was conducted in accordance with the guidelines of the World Medical Association Declaration of Helsinki (1964) and its seventh amendment (2013) and to the Consolidated Standards of Reporting Trials (CONSORT) (Figurec1). The objectives of the study, as well as the risks and benefits were explained to the patients and those who agreed to participate have signed a consent form.
The inclusion criteria of the study were: individuals of both genders aging between 18 and 35 years, classified as ASA I according to the American Society of Anesthesiologists, and who have symmetrical bilateral impacted mandibular third molar detected by a panoramic radiograph. Impacted teeth categorized as mesiaoangular (Winter classification) and class II position B (Pell and Gregory classification) were included. The patients had no infection, pain, trismus, and swelling at the time of surgery.
Patients who are smokers, with pericoronitis, active infection, systemic disorders, on long term steroids, pregnant and lactating women were excluded. Patients were also precluded if they had taken analgesics 24 hours before- and antibiotics one week before the surgery, and if the surgical procedure exceeded 30 minutes or if more than three cartridges of local anaesthesia were used during the procedure.
By implementing the split mouth model, each participant underwent two surgical procedures, with an interval of at least 4 weeks between them. Prior to the first procedure, randomization of the first side to be operated (right or left) was performed using the "heads or tails" technique using a coin, where the head represented the right side and tails the left side.
The study group (group I) received 1 ml (6 mg) of betamethasone (CKOÇAK FARMA, Turkey) injection to the pterygomandibular space. Each ml contains 3.0 mg betamethasone acetate and 3.0 mg betamethasone sodium phosphate. The control group (group II) received a corresponding volume of normal saline injected into the pterygomandibular space. To ensure blinding of the study, the solution was injected by a third person, who is not directly involved in the surgery nor in the postoperative visits.
Impacted mandibular third molar surgery was performed under local anesthesia, using 2% lidocaine hydrochloride with 1:80,000 concentration of adrenaline. Inferior alveolar nerve, lingual and buccal nerve block technique were performed. After profound anesthesia was achieved, the betamethasone, or the sham solution, was injected into the pterygomandibular space using 3 ml disposable plastic syringe and gauge 25 hypodermic needle. A standard Ward's incision was designed and the mucoperiosteal fap was reflected to expose the surgical site. A lingual flap was reflected, only when deemed to be necessary. Bone guttering was made using round No.8 and straight fissure carbide bur (no. 703) bur, under copious saline irrigation. The tooth was sectioned or removed as whole. It was then luxated and delivered using elevators and forceps. The socket was thoroughly irrigated with normal saline solution done, after the rough bone margins were trimmed and finally the wound was closed with 3-0 Vicryl suture. The duration of surgery was measured from the time of incision to placement of the last suture.
The patient was given the usual postoperative instructions, including ice pack application to the operated side for 20 minutes, with 20-minute intervals between applications, for the first day. The patient was advised to consume cold liquid diet in the first day, and soft diet for the next 5 days. In addition, twice daily mouth wash with chlorhexidine 0.12% for 5 days, starting the day after surgery. Patients were given three days course of broad-spectrum antibiotic (amoxicillin 500 mg every eight hours or clindamycin 300 mg every eight hours if a penicillin allergy existed) and paracetamol 1g as a rescue analgesic.
The Facial swelling and the degree of trismus was recorded by the same operator, preoperatively and on the first, third, and seventh postoperative days. The pain was recorded by the patient, at 8:00 am, using visual analogue scale (VAS) at 1-5 postoperative days. . The patients rated pain on a 10-cm VAS, from no pain (0) to the most severe pain (10). Number of analgesic tablets consumed by the patients ,during the first five postoperative days, was also calculated. Flexible tape was used for measuring the following facial distances: gonion-lip commissure, gonion-external canthus of the eye, tragus-lip commissure, tragus-soft tissue pogonion. The sum of the preoperative measurements was considered as a baseline for the side of the face being assessed. Subtracting the preoperative measurement from the postoperative one indicated the amount of facial swelling. The degree of trismus was assessed by measuring the distance between the incisal edges of the upper and lower central incisors, on maximum mouth opening, using a digital vernier Statistical analyses was performed using the statistical package SPSS software 25.0. Comparisons between the groups was carried out using an independent t test. The significance level was set at P < 0.05.
- Conditions
- Morbidity, Third Molars Extraction, Steroid Injection
- Being tested
- Betamethasone, normal saline
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BetamethasoneDrug
Also called Betamethasone injection ino the pterygomandibular space
The study group (group I) received 1 ml (6 mg) of betamethasone (CKOÇAK FARMA, Turkey) injection to the pterygomandibular space. Each ml contains 3.0 mg betamethasone acetate and 3.0 mg betamethasone sodium phosphate
normal salineDrug
normal saline
| Study group | Role | What they receive |
|---|---|---|
| betamethasone treated side | Experimental | Betamethasone was administered into the pterygomandibular space immediately before surgery Receives: Drug: Betamethasone |
| Control side | Placebo comparator | normal saline was administered into the pterygomandibular space immediately before surgery Receives: Drug: normal saline |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postoperative pain was assessed by patient self-report using a visual analogue scale (VAS; 0-10), where 0 indicated no pain and 10 indicated the worst imaginable pain.
postoperative pain assessed by the patient on VAS pain score
Measured: Pain scores were recorded immediately after surgery and daily for the first five days
Secondary outcomes (2)
trismus
degree of maximum mouth opening measured between the maxillary and mandibular central incisors using a digital vernier
Measured: Trismus was measured on the first, third, and seventh postoperative days
Facial swelling
Flexible tape was used for measuring the following facial distances: gonion-lip commissure, gonion-external canthus of the eye, tragus-lip commissure, tragus-soft tissue pogonion. The sum of the preoperative measurements was considered as a baseline for the side of the face being assessed. Subtracting the preoperative measurement from the postoperative one indicated the amount of facial swelling.
Measured: Facial swelling was measured on the first, third, and seventh postoperative days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Dec 2025
- Study start3 Jan 2022
- Primary completion21 Feb 2023
- Study completion26 Mar 2023
Why it stopped: There was a change in the protocol of the study
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MorbidityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Shehab Ahmed Hamad
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Shehab Ahmed Hamad, Kurdistan Higher Council of Medical Specialties
- Investigators
- Shehab Hamad, FFDRCSI, Principal investigator, Kurdistan Higher Council of Medical Specialties
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07297264
- Sponsor's protocol ID
- Betamethasone in MTM
- Status last verified
- Dec 2025
- First submitted
- 19 Apr 2023
- Last updated
- 22 Dec 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Betamethasone Injection Into the Pterygomandibular Space on Postoperative Sequelae of Impacted Lower Third Molar Surgery: A Randomized, Double-blind, Placebo-controlled Clinical Trial With a Split-mouth Design
- ClinicalTrials.gov ID
- NCT07297264
- Acronym / sponsor ID
- Betamethasone in MTM
- Conditions
- Morbidity, Third Molars Extraction, Steroid Injection
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: There was a change in the protocol of the study
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Shehab Ahmed HamadUniversity, hospital or other
- Study start
- 3 Jan 2022 (actual)
- Primary completion
- 21 Feb 2023 (actual)
- Study completion
- 26 Mar 2023 (actual)
- First posted
- 22 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Pain, swelling, and trismus are common sequalae of surgical removal of impacted third molars. The aim of this study is to evaluate effect of local administration of betamethasone, into the pterygomandibular space, on these sequalae
Detailed description
A prospective, single center, double-blind, randomized controlled design study was conducted between January 2022 and February 2023, in the department of oral and maxillofacial surgery, Rizgary teaching hospital, Erbil, Iraq. The participants were patients presented for the surgical removal of bilateral symmetrical impacted lower third molars. To achieve 95% power, a sample size of 40 patients with bilateral impacted third molars was required.
The study was approved by the Ethical Committee of the institutional board and was conducted in accordance with the guidelines of the World Medical Association Declaration of Helsinki (1964) and its seventh amendment (2013) and to the Consolidated Standards of Reporting Trials (CONSORT) (Figurec1). The objectives of the study, as well as the risks and benefits were explained to the patients and those who agreed to participate have signed a consent form.
The inclusion criteria of the study were: individuals of both genders aging between 18 and 35 years, classified as ASA I according to the American Society of Anesthesiologists, and who have symmetrical bilateral impacted mandibular third molar detected by a panoramic radiograph. Impacted teeth categorized as mesiaoangular (Winter classification) and class II position B (Pell and Gregory classification) were included. The patients had no infection, pain, trismus, and swelling at the time of surgery.
Patients who are smokers, with pericoronitis, active infection, systemic disorders, on long term steroids, pregnant and lactating women were excluded. Patients were also precluded if they had taken analgesics 24 hours before- and antibiotics one week before the surgery, and if the surgical procedure exceeded 30 minutes or if more than three cartridges of local anaesthesia were used during the procedure.
By implementing the split mouth model, each participant underwent two surgical procedures, with an interval of at least 4 weeks between them. Prior to the first procedure, randomization of the first side to be operated (right or left) was performed using the "heads or tails" technique using a coin, where the head represented the right side and tails the left side.
The study group (group I) received 1 ml (6 mg) of betamethasone (CKOÇAK FARMA, Turkey) injection to the pterygomandibular space. Each ml contains 3.0 mg betamethasone acetate and 3.0 mg betamethasone sodium phosphate. The control group (group II) received a corresponding volume of normal saline injected into the pterygomandibular space. To ensure blinding of the study, the solution was injected by a third person, who is not directly involved in the surgery nor in the postoperative visits.
Impacted mandibular third molar surgery was performed under local anesthesia, using 2% lidocaine hydrochloride with 1:80,000 concentration of adrenaline. Inferior alveolar nerve, lingual and buccal nerve block technique were performed. After profound anesthesia was achieved, the betamethasone, or the sham solution, was injected into the pterygomandibular space using 3 ml disposable plastic syringe and gauge 25 hypodermic needle. A standard Ward's incision was designed and the mucoperiosteal fap was reflected to expose the surgical site. A lingual flap was reflected, only when deemed to be necessary. Bone guttering was made using round No.8 and straight fissure carbide bur (no. 703) bur, under copious saline irrigation. The tooth was sectioned or removed as whole. It was then luxated and delivered using elevators and forceps. The socket was thoroughly irrigated with normal saline solution done, after the rough bone margins were trimmed and finally the wound was closed with 3-0 Vicryl suture. The duration of surgery was measured from the time of incision to placement of the last suture.
The patient was given the usual postoperative instructions, including ice pack application to the operated side for 20 minutes, with 20-minute intervals between applications, for the first day. The patient was advised to consume cold liquid diet in the first day, and soft diet for the next 5 days. In addition, twice daily mouth wash with chlorhexidine 0.12% for 5 days, starting the day after surgery. Patients were given three days course of broad-spectrum antibiotic (amoxicillin 500 mg every eight hours or clindamycin 300 mg every eight hours if a penicillin allergy existed) and paracetamol 1g as a rescue analgesic.
The Facial swelling and the degree of trismus was recorded by the same operator, preoperatively and on the first, third, and seventh postoperative days. The pain was recorded by the patient, at 8:00 am, using visual analogue scale (VAS) at 1-5 postoperative days. . The patients rated pain on a 10-cm VAS, from no pain (0) to the most severe pain (10). Number of analgesic tablets consumed by the patients ,during the first five postoperative days, was also calculated. Flexible tape was used for measuring the following facial distances: gonion-lip commissure, gonion-external canthus of the eye, tragus-lip commissure, tragus-soft tissue pogonion. The sum of the preoperative measurements was considered as a baseline for the side of the face being assessed. Subtracting the preoperative measurement from the postoperative one indicated the amount of facial swelling. The degree of trismus was assessed by measuring the distance between the incisal edges of the upper and lower central incisors, on maximum mouth opening, using a digital vernier Statistical analyses was performed using the statistical package SPSS software 25.0. Comparisons between the groups was carried out using an independent t test. The significance level was set at P < 0.05.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| betamethasone treated side | Experimental | Drug: BetamethasoneBetamethasone was administered into the pterygomandibular space immediately before surgery |
| Control side | Placebo comparator | Drug: normal salinenormal saline was administered into the pterygomandibular space immediately before surgery |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- healthy
- no infection
- no pain
- no limitation of mouth opening
- symmetrical bilateral impacted third molars (Mesioangular, CLASS II, Position B
Key exclusion criteria (4 listed)
- Infection
- systemic disease
- smokers
- operation time exceeding 30 minutes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BetamethasoneAlso: Betamethasone injection ino the pterygomandibular spaceThe study group (group I) received 1 ml (6 mg) of betamethasone (CKOÇAK FARMA, Turkey) injection to the pterygomandibular space. Each ml contains 3.0 mg betamethasone acetate and 3.0 mg betamethasone sodium phosphate | Drug | betamethasone treated side |
| normal salinenormal saline | Drug | Control side |
Primary outcome
Postoperative pain was assessed by patient self-report using a visual analogue scale (VAS; 0-10), where 0 indicated no pain and 10 indicated the worst imaginable pain.
Time frame: Pain scores were recorded immediately after surgery and daily for the first five days
postoperative pain assessed by the patient on VAS pain score
2 secondary outcomes
trismus
Time frame: Trismus was measured on the first, third, and seventh postoperative days
Facial swelling
Time frame: Facial swelling was measured on the first, third, and seventh postoperative days
Results and safety
The study was stopped early (reason given: There was a change in the protocol of the study). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Dec 2025.
Related trials for Morbidity
Active, not recruiting
Implementation of a Disparities in Labor Outcomes Dashboard
Labor Induction, Cesarean Birth
Not yet recruiting
Prediction and Prevention of Postoperative Mortality and Morbidity
Dementia, Postoperative Delirium (POD)
Recruiting
Safety and Efficacy of NTP in Thyroid Surgery: Pilot Study on Morbidity Prevention and Adjuvant Oncological Control
Thyroid Diseases, Wound Healing
Active, not recruiting
The Maternal Health Multilevel Intervention for Racial Equity (MIRACLE) Project
Maternal Morbidity and Mortality, Health Disparities
Recruiting
Scaling up Maternal Health Equity Best Practices
Maternal Mortality Disparities, Maternal Morbidity Disparities
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Shehab Hamad, FFDRCSI principal investigator
Kurdistan Higher Council of Medical Specialties
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Betamethasone and normal saline in people with Morbidity and Third Molars Extraction, run by Shehab Ahmed Hamad at 1 site in Iraq.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 22 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Iraq. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: There was a change in the protocol of the study). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postoperative pain was assessed by patient self-report using a visual analogue scale (VAS; 0-10), where 0 indicated no pain and 10 indicated the worst imaginable pain. (time frame: Pain scores were recorded immediately after surgery and daily for the first five days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Dec 2025.